Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Boomfish Wealth Group LLC

Boomfish Wealth Group LLC lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,975 shares of the pharmaceutical company’s stock after selling 107 shares during the quarter. Vertex Pharmaceuticals comprises about 1.5% of Boomfish Wealth Group LLC’s portfolio, making the stock its 27th biggest holding. Boomfish Wealth Group LLC’s holdings in Vertex Pharmaceuticals were worth $2,332,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of VRTX. Nicholas Hoffman & Company LLC. boosted its position in shares of Vertex Pharmaceuticals by 3.9% during the 4th quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock worth $259,000 after purchasing an additional 24 shares during the period. Hohimer Wealth Management LLC boosted its holdings in Vertex Pharmaceuticals by 0.8% during the 4th quarter. Hohimer Wealth Management LLC now owns 2,932 shares of the pharmaceutical company’s stock valued at $1,193,000 after acquiring an additional 24 shares during the period. Johnson Financial Group Inc. increased its stake in Vertex Pharmaceuticals by 2.5% during the fourth quarter. Johnson Financial Group Inc. now owns 1,001 shares of the pharmaceutical company’s stock worth $407,000 after purchasing an additional 24 shares during the period. Quent Capital LLC lifted its position in shares of Vertex Pharmaceuticals by 6.0% during the second quarter. Quent Capital LLC now owns 423 shares of the pharmaceutical company’s stock worth $198,000 after purchasing an additional 24 shares in the last quarter. Finally, Trust Co. of Vermont boosted its stake in shares of Vertex Pharmaceuticals by 7.9% in the second quarter. Trust Co. of Vermont now owns 326 shares of the pharmaceutical company’s stock valued at $153,000 after purchasing an additional 24 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 7,073 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $17,920,000. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Reshma Kewalramani sold 1,565 shares of the business’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $457.00, for a total value of $715,205.00. Following the sale, the chief executive officer now directly owns 121,374 shares in the company, valued at approximately $55,467,918. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce I. Sachs sold 7,073 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the sale, the director now directly owns 40,000 shares in the company, valued at approximately $17,920,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 55,703 shares of company stock worth $26,615,855. Corporate insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on VRTX. HC Wainwright lifted their target price on Vertex Pharmaceuticals from $500.00 to $600.00 and gave the company a “buy” rating in a report on Monday, August 5th. Cantor Fitzgerald reiterated an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, August 2nd. BMO Capital Markets raised their price target on Vertex Pharmaceuticals from $480.00 to $500.00 and gave the company an “outperform” rating in a research note on Friday, May 31st. Guggenheim upped their price objective on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Truist Financial restated a “buy” rating and set a $550.00 target price (up previously from $508.00) on shares of Vertex Pharmaceuticals in a research note on Monday, August 5th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $485.91.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX traded up $5.37 during midday trading on Friday, hitting $477.37. The stock had a trading volume of 1,181,337 shares, compared to its average volume of 1,219,119. The company has a market capitalization of $123.19 billion, a PE ratio of 30.98 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 1 year low of $340.83 and a 1 year high of $510.64. The stock has a 50 day moving average price of $480.54 and a two-hundred day moving average price of $442.24. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The business had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.66 billion. During the same period last year, the company posted $3.53 earnings per share. The business’s quarterly revenue was up 6.1% on a year-over-year basis. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.